行业盛典 再启新程|第七届中国医药创新与投资大会初版日程发布

QIN Zhijie

CMO, Wuhan Healthgen Biotechnology Corp.

QIN Zhijie, MD., PhD., finished his medical school course at Shandong Medical College (current the Shandong University Qilu Medical School). He then completed his doctoral work at the Institute of Biophysics at Chinese Academy of Sciences, and Kansai Medical University in Japan, in biochemistry, biophysics, and molecular biology. He has been extensively trained in biomedicine at the University of California at Santa Cruz working as a postdoctoral researcher and succeeded the USMLE (US Medical License Examinations) and obtains the Certificate of Medical Degree from ECFMG in United States. From there he has worked as a senior scientist at TOSK, a start-up pharmaceutical firm, to develop new small molecular drugs in oncology. After TOSK, he jointed a biotech company named AnaSpec working as a senior scientist in antibody development and left as a manager of Antibody department. Later, Dr. Qin joined ReLIA Diagnostic as Director of Marketing and Clinical Medicine. In 2018, Dr. Qin jointed TenNor Pharmaceutics at Suzhou as Vice President of Clinical Development to take charge in the clinical studies of their novel anti-microbe products, and successfully conducted Phase 1 and Phase 2 studies internationally. In 2021, Dr. Qin jointed Wuhan Healthgen in the role of Chief Medical Officer to lead the clinical study team.